Masumoto, Miwa
Kuragano, Takahiro
Takata, Chisa
Fukui, Risako
Mihara, Yuki
Okamoto, Rina
Iwasaki, Takahide
Ookawa, Satoshi
Aichi, Makoto
Yahiro, Mana
Kida, Arithoshi
Nanami, Masayshi
Article History
Received: 14 March 2021
Accepted: 25 July 2021
First Online: 14 August 2021
Declarations
:
: Takahiro Kuragano declares having grants from Chugai Pharmaceutical, Pharmaceutical Company, Ono Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., and Kyowa Kirin and received a speaker fee from Kyowa Kirin, Fuso Pharmaceutical Industries, Ltd., and Bayer Yakuhin, Ltd. Takahiro Kuragano received an advisory board fee from Astellas Pharma Inc. and Chugai Pharmaceutical.
: The protocol was approved by the Ethics Review Board of the Hyogo College of Medicine (approval number 419) in accordance with the ethical principles outlined in the 1975 Declaration of Helsinki as revised in 2013.
: Written informed consent was obtained from all patients.
: Written informed consent was obtained from all patients.